STOCK TITAN

SI-BONE to Present at the 7th Annual Truist 2021 Life Sciences Summit and the 2021 Bank of America Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SANTA CLARA, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 7th Annual Truist Securities 2021 Life Sciences Summit and the 2021 Bank of America Health Care Conference.

For the 7th Annual Truist Securities 2021 Life Sciences Summit, SI-BONE’s management is scheduled for a Fireside Chat on Wednesday, May 5, 2021 at 2:40 p.m. Eastern Time / 11:40 a.m. Pacific Time.

For the 2021 Bank of America Health Care Conference, SI-BONE’s management is scheduled to present on Wednesday, May 12, 2021 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time.

Interested parties may access a live and archived webcast of the events on the “Investors” section of the company’s website at: www.si-bone.com.

About SI-BONE

SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved. 04222021

Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com


SI-BONE, Inc.

NASDAQ:SIBN

SIBN Rankings

SIBN Latest News

SIBN Stock Data

614.78M
37.81M
2.38%
98.43%
5.95%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SANTA CLARA

About SIBN

si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al